MedTrace Logo

MMR and Varicella Vaccine in Premature Infants

NCT00156559 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2015-09-17

No results posted yet for this study

Summary

This research is designed to address the question, "Does the relative deficit in vaccine immunogenicity in extremely premature infants persist beyond the first 6 months of life?" We propose to measure the immunogenicity of varicella and mumps-measles-rubella vaccines in relatively healthy, 12-to-15 month-old children born at \<29 weeks gestation, when compared to full-term infants, as measured by the relevant viral serologies.

Conditions

  • Chickenpox
  • Rubella
  • Rubeola
  • Mumps

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Carl T. D'Angio, MD · University of Rochester

Eligibility

Min Age
12 Months
Max Age
16 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156559 on ClinicalTrials.gov